血清HE4水平在子宫内膜癌中的研究进展-国际医学与数据杂志-CSCIED科技核心评价数据库-手机版

血清HE4水平在子宫内膜癌中的研究进展

Research progress of serum HE4 level in endometrial carcinoma

ES评分 0 浏览量：471 下载量：0

DOI	10.12208/j.ijmd.20240037
刊名	国际医学与数据杂志 International Journal of Medicine and Data
年，卷(期)	2024, 8(3)
作者	时子菲,周皓宇,李颖洁,翟菲菲,陈燕*,
作者单位	华北理工大学临床医学院河北唐山 ;
摘要	子宫内膜癌（Endometrial Cancer, EC）是女性生殖系统常见的恶性肿瘤之一，其发病率和死亡率在全球范围内均呈上升趋势。近年来，随着血清肿瘤分子标志物研究的深入，血清人附睾蛋白4（HE4）在子宫内膜癌的诊断、病情评估、治疗及预后中的作用日益受到关注。本文就血清HE4水平与子宫内膜癌临床病理特征之间的关系及其临床诊断与预后价值的相关研究进行综述，以期为子宫内膜癌的临床诊断和治疗预后提供理论依据。
Abstract	Endometrial Cancer (EC) is one of the most common malignancies of the female reproductive system, and its morbidity and mortality are on the rise worldwide. In recent years, with the deepening of the research on serum tumor molecular markers, the role of serum human epididymal protein 4 (HE4) in the diagnosis, evaluation, treatment and prognosis of endometrial cancer has attracted increasing attention. This article reviews the relationship between serum HE4 level and the clinicopathological features of endometrial cancer, as well as its clinical diagnosis and prognostic value, in order to provide theoretical basis for the clinical diagnosis and treatment of endometrial cancer.
关键词	HE4；子宫内膜癌；诊断；临床病理特征；预后
KeyWord	HE4; Endometrial cancer; Diagnosis; Clinicopathological features; prognosis
基金项目
页码	57-60

参考文献
相关文献

[1] 张一琼, 于江燕, 朱元方, 等. 子宫内膜癌肿瘤微环境的研究进展
[J]. 现代肿瘤医学, 2016, 24(16): 2651-2655.
[2] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and MortalityWorldwide for 36 Cancers in 185 Countries
[J]. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209-249.
[3] C Kirchhoff, I Habben, R lvell, et al. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors
[J]. Biology of Reproduction, 1991, 45(2): 350-7.
[4] 赵灵琴, 陈曦, 陈鲁, 等. 人附睾分泌蛋白4和CA125联合检测在子宫内膜恶性肿瘤与子宫良性肿瘤鉴别诊断中的价值
[J]. 中国癌症杂志, 2012, 22(11): 5.
[5] Bignotti E, Ragnoli M, Zanotti L, et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients
[J]. British Journal Cancer, 2011, 104(9): 1418-1425.
[6] Li J, Wang X, Qu W, et al. Comparison of serum human epididymis protein 4 and CA125 on endometrial cancer detection: A meta-analysis
[J]. Clinica Chimica Acta, 2019, 488: 215-220.
[7] Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up
[J]. International Journal of Gynecologic Cancer, 2016, 26(1): 2–30.
[8] Kalogera E, Scholler N, Powless C, et al. Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer
[J]. Gynecologic Oncology, 2012, 124(2): 270-275.
[9] Brennan D J, Hackethal A, Metcalf A M, et al. Serum HE4 as a prognostic marker in endometrial cancer—a population based study
[J]. Gynecologic Oncology, 2014, 132(1): 159-165.
[10] 陈燕娥, 吴学明, 温云花. 子宫内膜癌患者血清HE4, CA125及 CA19-9 的表达及与临床病理特征的关系
[J]. 中国老年学杂志, 2017, 37(015): 3787-3789.
[11] Espiau Romera A, Cuesta Guardiola T, Benito Vielba M, et al. HE 4 tumor marker as a predictive factor for lymphatic metastasis in endometrial cancer
[J]. International Journal of Gynecology & obstetrics, 2020, 149(3): 265-268.
[12] Brennan D J, Hackethal A, Mann K P, et al. Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance
[J]. Bmc Cancer, 2015, 15(1): 33.
[13] Abbink K, Zusterzeel P L, Geurts-Moespot A J, et al. HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients
[J]. Tumour Biology the Journal of the International Society for Oncodevelopmental Biology & Medicine, 2018, 40(2): 1010428318757103.
[14] 刘光泉, 黄可, 胡凯, 等. D-dimer和HE4联合检测在子宫内膜癌诊断中的应用
[J]. 南京医科大学学报(自然科学版), 2020, 40(12): 1852-1854.
[15] 陈毅红, 杨汉才, 罗强, 等. 血清HE4, CA125联合血浆D-二聚体检测在子宫内膜癌诊断中的应用价值
[J]. 中国卫生标准管理, 2023, 14(19): 46-49.
[16] 兰新志. 血清HE4, CA125和血浆D-二聚体在子宫内膜癌的表达及联合检测的临床价值
[J]. 实验与检验医学, 2019, 37(5): 916-918.

引用本文

时子菲,周皓宇,李颖洁,翟菲菲,陈燕*. 血清HE4水平在子宫内膜癌中的研究进展 [J]. 国际医学与数据杂志. 2024; 8; (3). 57 - 60.

文献评论

相关学者

相关机构